Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom

por Suri, Gaurav, Chandiwana, David, Lee, Adam, Mistry, Rohit
Publicado 2019

Patient experiences with patient-reported outcome measures in metastatic breast cancer trials: qualitative interviews

por Romano, Carla, Harris, Nimanee, Gnanasakthy, Ari, D’Alessio, Denise, Chandiwana, David
Publicado 2022

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer

por Forsythe, Anna, Chandiwana, David, Barth, Janina, Thabane, Marroon, Baeck, Johan, Tremblay, Gabriel
Publicado 2018

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer

por Tremblay, Gabriel, Chandiwana, David, Dolph, Mike, Hearnden, Jaclyn, Forsythe, Anna, Monaco, Mauricio
Publicado 2018

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom

por Amdahl, Jordan, Diaz, Jose, Sharma, Arati, Park, Jinhee, Chandiwana, David, Delea, Thomas E.
Publicado 2017

Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil

por Buehler, Anna Maria, Dionne, Pierre-Alexandre, Chandiwana, David, Pathak, Purnima, Igho-Osagie, Ebuwa
Publicado 2022

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?

por Forsythe, Anna, Chandiwana, David, Barth, Janina, Thabane, Marroon, Baeck, Johan, Shor, Anastasiya, Tremblay, Gabriel
Publicado 2018

Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribocic...

por Verma, Sunil, O’Shaughnessy, Joyce, Burris, Howard A., Campone, Mario, Alba, Emilio, Chandiwana, David, Dalal, Anand A., Sutradhar, Santosh, Monaco, Mauricio, Janni, Wolfgang
Publicado 2018

Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer

por Turner, Stuart, Chia, Stephen, Kanakamedala, Hemanth, Hsu, Wei‐Chun, Park, Jinhee, Chandiwana, David, Ridolfi, Antonia, Yu, Chu‐Ling, Zarate, Juan Pablo, Rugo, Hope S.
Publicado 2021

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer

por Fasching, Peter A, Delea, Thomas E, Lu, Yen-Shen, De Boer, Richard, Hurvitz, Sara A, Moynahan, Aaron, Chandiwana, David, Lanoue, Brad, Hu, Huilin, Thuerigen, Astrid, O’Shaughnessy, Joyce
Publicado 2021

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results f...

por Harbeck, Nadia, Franke, Fabio, Villanueva-Vazquez, Rafael, Lu, Yen-Shen, Tripathy, Debu, Chow, Louis, Babu, Govind K, Im, Young-Hyuck, Chandiwana, David, Gaur, Anil, Lanoue, Brad, Rodriguez-Lorenc, Karen, Bardia, Aditya
Publicado 2020

Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer

por Tripathy, Debu, Curteis, Tristan, Hurvitz, Sara, Yardley, Denise, Franke, Fabio, Babu, K. Govind, Wheatley-Price, Paul, Im, Young-Hyuck, Pencheva, Radost, Eddowes, Lucy A., Dionne, Pierre-Alexandre, Chandiwana, David, Pathak, Purnima, Lanoue, Brad, Harbeck, Nadia
Publicado 2022

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

por Fasching, Peter A., Beck, J. Thaddeus, Chan, Arlene, De Laurentiis, Michele, Esteva, Francisco J., Jerusalem, Guy, Neven, Patrick, Pivot, Xavier, Bianchi, Giulia V., Martin, Miguel, Chandiwana, David, Lanoue, Brad, Ridolfi, Antonia, Wang, Yingbo, Rodriguez Lorenc, Karen, Nusch, Arnd
Publicado 2020